gp100 209-217 mutant (HLA-A*02:01) 210M
Prices plus VAT plus shipping costs
Delivery time 3 weeks
sterile and endotoxin free
Delivery Format: The product is supplied freeze dried.
- Order number: EP07860_1
gp100 209-217 Pos. 210M (HLA-A*02:01) IMDQVPFSV is a linear peptidic epitope studied as part of Melanoma antigen preferentially expressed in tumors from Homo sapiens (human). This epitope has been studied for immune reactivity in several publication, tested in T cell assays and MHC ligand assays. This modified gp100 peptide amino acids 209 to 217 is a MHC-associated HLA-A2.1-restricted epitope derived from melanoma antigene. It can be processed, presented, and recognized by T cells. Alteration of the gp100 209-217 peptide to gp100 209-217 Met2 at the second amino acid changing threonine to a methionine was found to increase the affinity for MHC-associated HLA-A2.1 resulting in enhanced induction of T cells reactive to native gp100
Sequence: | IMDQVPFSV | |
Gene: | PMEL | |
Delivery: | 3 weeks | |
C-Terminus: | OH | |
N-Terminus: | H | |
Purity: | 95% | |
Amount: | 1 mg | |
Counter Ion: | TFA | |
Protein: | Melanocyte protein PMEL | |
Species: | Human | |
Allele: | HLA-A*02:01 | |
Application : | T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune response | |
Indication : | Cancer, Epithelium, Melanoma |
Protocols and Tips
Data sheets